Clinical Trials Logo

Pseudohypoparathyroidism clinical trials

View clinical trials related to Pseudohypoparathyroidism.

Filter by:
  • Enrolling by invitation  
  • Page 1

NCT ID: NCT04240821 Enrolling by invitation - Clinical trials for Pseudohypoparathyroidism

Theophylline for Treatment of Pseudohypoparathyroidism

Start date: May 22, 2020
Phase: Phase 2
Study type: Interventional

Pseudohypoparathyroidism is a genetic disorder with limited treatment options, characterized by early-onset obesity, short stature, hormone resistance and cognitive impairment. This phase 2 clinical trial will test the efficacy of theophylline, a phosphodiesterase inhibitor, in pseudohypoparathyroidism. We hypothesize that theophylline will cause weight loss, improve glucose tolerance and decrease hormone resistance in children and young adults.